ID   SK-RC-26B
AC   CVCL_3120
SY   SK-RC-26b; SK-RC 26B; SK RC 26b; SKRC-26B; SK-RC26b; RCC 26b; RCC26b
DR   BTO; BTO:0004781
DR   IARC_TP53; 26508
DR   Wikidata; Q54954563
RX   PubMed=2386958;
RX   PubMed=15026329;
RX   PubMed=27993170;
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/sk-rc-m-metastatic-human-renal-cell-carcinoma-rcc-cell-line-collection
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): MSKCC
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11
ST   D18S51: 13
ST   D19S433: 15.2
ST   D21S11: 28,30
ST   D2S1338: 19
ST   D3S1358: 16
ST   D5S818: 13
ST   D7S820: 8,9
ST   D8S1179: 14
ST   FGA: 20
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 14
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_6183 ! SK-RC-26A
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 20
//
RX   PubMed=2386958;
RA   Ebert T., Bander N.H., Finstad C.L., Ramsawak R.D., Old L.J.;
RT   "Establishment and characterization of human renal cancer and normal
RT   kidney cell lines.";
RL   Cancer Res. 50:5531-5536(1990).
//
RX   PubMed=15026329; DOI=10.1158/0008-5472.CAN-03-1541;
RA   Gurova K.V., Hill J.E., Razorenova O.V., Chumakov P.M., Gudkov A.V.;
RT   "p53 pathway in renal cell carcinoma is repressed by a dominant
RT   mechanism.";
RL   Cancer Res. 64:1951-1958(2004).
//
RX   PubMed=27993170; DOI=10.1186/s12943-016-0565-8;
RA   Brodaczewska K.K., Szczylik C., Fiedorowicz M., Porta C.,
RA   Czarnecka A.M.;
RT   "Choosing the right cell line for renal cell cancer research.";
RL   Mol. Cancer 15:83.1-83.15(2016).
//